1 Sensitivity analyses for the REFLUX RCT Our motivating example trial had over 50% missing cost-effectiveness outcomes, with a few missing data in the baseline covariate. As primary analysis, we performed MI and full Bayesian analyses, that intrinsically obtain a predictive posterior distribution for these missing values, and reported the results of these analyses in the main text.
: Estimated cost-effectiveness for the REFLUX RCT, over a time horizon of five years according to ITT and alternative methods for estimating the CACE based on complete cases. Treatment switches are defined within the first year post randomisation. Costs and INB numbers rounded to the nearest integer. As can be seen in Table A1 , the conclusions each model reaches are not substantially changed from those under MAR (either using MI or full Bayesian), presented in the main text.
Incremental costs, QALYs and INB of surgery vs medicine

Sensitivity analysis of the BFL to choice of priors
We now study the sensitivity of the BFL model to the choice of priors for the parameters in the model. Recall that this model can be written as 
Originally, we chose normal priors for the regression coefficients, β m,j ∼ N (0, 10 2 ), for j ∈ {0, 1, 2}, m ∈ {0, 1}, and a Wishart prior for the inverse of Σ (Gelman and Hill, 2006) .
Here, we first vary the prior distribution for Σ, and assume a structured covariance matrix (see Congdon (2007) example 5.8, and Lunn et al. (2012) , example 9.1.4). Thus, we write: 
and assumed the following priors
In a secondary sensitivity analysis, we assume a Wishart prior for Σ as before, but used uniform priors for the regression coefficients, β m,j ∼ Unif[−10, 10], for j ∈ {0, 1, 2}, m ∈ {0, 1}. We did these changes on both available cases and complete cases. The results corresponding to INB are reported in Table A2 . Figure A1 : Median Bias for scenarios with 70% non-compliance and sample sizes of (a) n = 100 (top) and (b) n = 1000.
Results are stratified by cost distribution, and correlation between cost and QALYs. The dotted line represents zero bias. Results for 2sls (not plotted) are identical to those for 3sls; uBGN was not applied to Normal cost data. Table A4 : CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 70% non-compliance, moderate correlation between outcomes and sample size n = 100. uBGN was not applied in settings with normal cost data. Table A6 : CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 30% non-compliance, high correlation between outcomes and sample size n = 100. uBGN was not applied in settings with normal cost data. Table A8 : CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 70% non-compliance, high correlation between outcomes and sample size n = 100. uBGN was not applied in settings with normal cost data. 
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